Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer

17 Aug 2021

Abstract excerpt

Triple-negative breast cancer (TNBC) is defined by the absence of estrogen receptor and progesterone receptor and human epidermal growth factor receptor 2 (HER2) overexpression. This malignancy, representing 15-20% of breast cancers, is a clinical challenge due to the lack of targeted treatments, higher intrinsic aggressiveness, and worse outcomes than other breast cancer subtypes. Immune checkpoint inhibitors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34439290
DOI: 10.3390/cancers13164139

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast CancerPMID 34439290Read ↗

DNA methylation and immune evasion in triple-negative breast cancer: challenges and therapeutic opportunitiesSemantic proximity Read ↗

New Biomarkers and Treatment Advances in Triple-Negative Breast CancerSemantic proximity Read ↗

Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategiesSemantic proximity Read ↗

Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancerSemantic proximity Read ↗

Advances in immunotherapy for triple-negative breast cancerSemantic proximity Read ↗

Epigenetic Alterations in Triple-Negative Breast Cancer—The Critical Role of Extracellular MatrixSemantic proximity Read ↗

Targeting DNA Methylation for Treating Triple-Negative Breast CancerSemantic proximity Read ↗

New Insights into the Implication of Epigenetic Alterations in the EMT of Triple Negative Breast CancerSemantic proximity Read ↗

Epigenetics of Triple-Negative Breast Cancer via Natural CompoundsSemantic proximity Read ↗

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast CancerSemantic proximity Read ↗

How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategiesSemantic proximity Read ↗

Targeting Triple‐Negative Breast Cancer: Resistance Mechanisms and Therapeutic AdvancementsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.